Market revenue in 2023 | USD 325.6 million |
Market revenue in 2030 | USD 702.2 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 51.54% in 2023. Horizon Databook has segmented the India biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
India was the most lucrative market among the developing nations; however, new regulations have limited attention of many global companies. Owing to falling percentage of outsourcing activities Indian government is taking initiatives and relaxing regulations so that it receives more outsourcing projects.
For instance, in May 2015, the Ministry of Health made accreditation compulsory for clinical trial centers, ethics committees, and investigators. Noncompliance with the regulations will lead to loss of accreditation.
In February 2015, the Central Drugs Standard Control Organization (CDSCO) passed a bill improving the subject compensation as well as involvement of trial regulators. If the trial causes permanent disability, the subject has to be compensated with 90% more than what he would have been compensated with on a regular basis.
Horizon Databook provides a detailed overview of country-level data and insights on the India biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into India biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account